Page 9 - Eric Schoen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Feb 22, 2021 AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences Inc., (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease. Official EOP2 meeting minutes indicate FDA and Cassava Sciences agree on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in A...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for ... Cassava Sciences, Inc.February 8, 2021 GMT AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced significant program progress and expected milestones for 2021. “We started 2021 with tremendous momentum, led by results of a 6-month interim analysis from an...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim ... Cassava Sciences, Inc.February 2, 2021 GMT - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 - - Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program - AUSTIN, Texas, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis fr...